

Jan KrÄjnke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4621240/publications.pdf>

Version: 2024-02-01

45
papers

5,107
citations

279701

23
h-index

254106

43
g-index

45
all docs

45
docs citations

45
times ranked

7311
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 1009.	5.8	28
2	Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn. <i>Experimental Hematology</i> , 2021, 93, 61-69.e4.	0.2	1
3	Triggering T-cell activity in CLL. <i>Blood</i> , 2021, 137, 150-151.	0.6	1
4	The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. <i>Cancer Immunology Research</i> , 2021, 9, 265-278.	1.6	26
5	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	2.0	2
6	Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2391-2402.	2.5	10
7	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
8	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021, 39, 3318-3327.	0.8	44
9	Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1733-1738.	1.3	25
10	Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020, 34, 404-415.	3.3	16
11	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
12	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020, 34, 1182-1186.	3.3	39
13	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73
14	Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. <i>Cancers</i> , 2020, 12, 3764.	1.7	13
15	Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. <i>Chemical Science</i> , 2020, 11, 3474-3486.	3.7	77
16	PROTAC-mediated crosstalk between E3 ligases. <i>Chemical Communications</i> , 2019, 55, 1821-1824.	2.2	74
17	Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	10
18	A MedChem toolbox for cereblon-directed PROTACs. <i>MedChemComm</i> , 2019, 10, 1037-1041.	3.5	44

#	ARTICLE	IF	CITATIONS
19	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	5.8	87
20	Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open, 2019, 4, e000583.	2.0	22
21	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia, 2018, 32, 30-37.	3.3	50
22	Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 379, 1873-1874.	13.9	6
23	Homo-PROTACs for the Chemical Knockdown of Cereblon. ACS Chemical Biology, 2018, 13, 2771-2782.	1.6	114
24	Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). Blood, 2018, 132, 1979-1979.	0.6	1
25	IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia, 2017, 31, 1363-1367.	3.3	38
26	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. Haematologica, 2017, 102, 2039-2047.	1.7	72
27	Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma. Oncotarget, 2017, 8, 106163-106164.	0.8	4
28	The molecular mechanism of thalidomide analogs in hematologic malignancies. Journal of Molecular Medicine, 2016, 94, 1327-1334.	1.7	36
29	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. Haematologica, 2016, 101, e454-e456.	1.7	7
30	Lenalidomide induces ubiquitination and degradation of CK1 α in del(5q) MDS. Nature, 2015, 523, 183-188.	13.7	648
31	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia, 2015, 29, 1942-1945.	3.3	18
32	Lenalidomide induces degradation of IKZF1 and IKZF3. OncoImmunology, 2014, 3, e941742.	2.1	63
33	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science, 2014, 343, 301-305.	6.0	1,371
34	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica, 2014, 99, e133-e135.	1.7	11
35	Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q). Blood, 2014, 124, 4-4.	0.6	19
36	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood, 2013, 122, 100-108.	0.6	242

#	ARTICLE	IF	CITATIONS
37	Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3. <i>Blood</i> , 2013, 122, LBA-5-LBA-5.	0.6	1
38	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013, 122, 2555-2555.	0.6	0
39	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	0.6	66
40	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012, 120, e83-e92.	0.6	131
41	Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 2709-2716.	0.8	355
42	Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. <i>Leukemia</i> , 2010, 24, 438-449.	3.3	125
43	Comment on "Integrative genomic profiling of human prostate cancer". <i>Leukemia</i> , 2010, 24, 1970-1972.	3.3	4
44	<i>IDH1</i> and <i>IDH2</i> Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With <i>NPM1</i> Mutation Without <i>FLT3</i> Internal Tandem Duplication. <i>Journal of Clinical Oncology</i> , 2010, 28, 3636-3643.	0.8	728
45	Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs. <i>Journal of Virology</i> , 2004, 78, 3436-3446.	1.5	158